Compares bypass surgery and stenting in people with heart disease and heart failure
Tests bypass surgery against stenting in adults with narrowed heart arteries.
Plain-language title generated from the registry record
Registry title: STICH-3.0 International Trial Consortium
Key facts
- Where
- Gothenburg, SwedenSee the site
Where in Sweden
- Dep of Cardiology, Sahlgrenska University HospitalGothenburg, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT05761067
- Record updated
- 25 September 2024
- Original description
The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD.Read full original descriptionShow less
The CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH) 3.0 International Trial Consortium
The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD.
Individual patient data from similar national RCTs independently powered for different efficacy endpoints will be pooled, harmonized, and analyzed.
The primary endpoint is all-cause mortality.
Inclusion: Age >18 years; LVEF ≤40%; Extensive coronary artery disease (typically defined as a British Cardiovascular Intervention Society jeopardy score of ≥6, on a scale from 0 to 12, with higher scores indicating greater extent of disease).
Exclusion: Decompensated heart failure requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ ventricular assist device therapy less than 48 hours prior to randomization; Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) indicating the need for surgical repair/replacement; Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy; Pregnancy; Circumstances likely to lead to poor treatment adherence; STEMI within 72 hours; PCI within 3 months.